Clinical Trial

Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia

Study acronym: IBIS XLH
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to better understand how X-linked hypophosphatemia (XLH) affects the body and daily life. Phosphate levels are critical in managing XLH, we aim to study how these levels change in patients taking burosumab and how they relate to bone health, overall disease burden and XLH-related conditions.
Trial Details
NCT Number NCT07607600
Lead Sponsor Novo Nordisk A/S
Conditions X-linked Hypophosphatemia (XLH)
Enrollment 100 participants
Start Date 2026-07-07
Primary Completion 2030-07-07 (estimated)
Study Completion 2030-07-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-26